Talk:Ezetimibe

message: Can someone please check the side effects occurence?  It's using the symbol "≥" 1%, saying that side effects occur in more than or (at minimum) 1% of patients.  This seems to be a typo to me, and probably intends to say "≤ 1%".  But I don't have actual knowledge, so if someone with accurate numbers can check and fix it if needed, that'd be fab.—Preceding unsigned comment added by Bugsi (talk • contribs) 04:30, 15 March 2007
It says "common side effects" which I believe would mean more than or at minimum 1% of patients; if it were less than 1% then it wouldn't fall under common. I do think if anyone comes across reliable numbers on each of the side-effects to get their actual incidence that would be preferable, though. Ryan Pedigo (talk) 20:03, 3 April 2010 (UTC)
thread_title: Can

message: interesting article by ben goldacre in the guardian here, or repeated in goldacre's blog, with comments, here, which someone might want to incorporate. goldacre's articles tend to be quite polemical and wouldn't be my first choice for a citation though--Mongreilf (talk) 17:09, 5 January 2008 (UTC)
replies: text: thanks guys--Mongreilf (talk) 16:43, 15 January 2008 (UTC)
thread_title:  Bad Science 

message: The article says that that Zetia was intended to reduce the growth of plaques, but it resulted in the growth of plaques less than the placebo.  Doesn't that mean it DID actually reduce the growth of plaques?  If something reduces the growth of children, it doesn't mean the children get smaller, only that they are smaller compared to what they would have been, i.e. less growth.  
Mauvila (talk) 08:34, 8 June 2008 (UTC)
thread_title:  Growth of plaques 

message: It's been a couple of months since ARBITER-6 was terminated due to the results of a 'prespecified, blinded interim analysis'. This essentially means that ezetimibe is clearly better than, or worse than, niacin. I'll keep my personal opinion on that out of this discussion, but this will be very interesting to add to the article once the results become available in the NEJM or wherever they end up publishing. Antelan 21:31, 5 October 2009 (UTC)
replies: text: Looks like it's hard to make any conclusion. However, ARBITER-6 should be addressed in this article. I see that someone added it but was reverted for plagiarism. Antelan 18:28, 20 November 2009 (UTC)
thread_title:  ARBITER-6 

message: "achieve their LDL (or bad cholesterol) targets" <- If the "bad cholesterol" bit absolutely MUST be included, it should be with quotation marks or preceded by "so-called".Bstard12 (talk) 06:33, 18 August 2013 (UTC)
thread_title:  LDL is neither "bad" nor cholesterol 

message: This is an interesting statement: "The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) results support guidelines presented at last year’s Scientific Sessions by the American Heart Association and American College of Cardiology." http://blog.heart.org/study-shows-cholesterol-combination-significantly-reduced-cardiovascular-risks/ User:Fred Bauder Talk 10:26, 18 November 2014 (UTC)
replies: text: what are you suggesting we do with respect to the article? Jytdog (talk) 12:11, 18 November 2014 (UTC)
replies: text: That, while being suitably cautious about medical information, we use reliable sources to report major announcements and controversies. I think medical events that are not medical in themselves require much less stringent vetting than information about the efficacy of a drug such as this and how it compares to other options. For example the funding of the study by its maker is interesting, as is its announcement at the AHA convention. User:Fred Bauder Talk 13:02, 18 November 2014 (UTC)

text: Guidelines for treatment in this instance are also interesting as the latest guideline recommend treatment with statins only. This seems to upset the apple cart. But are there differing AHA guidelines? User:Fred Bauder Talk 13:04, 18 November 2014 (UTC)
replies: text: guideline-issuing authorities are not going to change anything based on results presented at a conference.  they will wait til the study is actually published, read it, debate it, and in a few months they will probably update their guidelines, at least to include discussion of this trial (it may or may not change the actual treatment guideline which is what we care about).    in the meantime, the medical community will also be waiting for the full study to be published, and will stew on it, and then the reviews will start to come.  Those are the kind of WP:SECONDARY sources upon which we base health-related content in WP - statements by major medical and scientific bodies, and reviews published in the biomedical literature.  Not popular media, not blogs, not conference abstracts, not even WP:PRIMARY sources in the research is first actually published in a peer-reviewed journal.  Secondary sources.  This is actually true of all of WP, as described in the policies WP:NPOV, WP:OR, and WP:VERIFY, and the guidelines WP:RS and the guideline for health related content, WP:MEDRS.  Jytdog (talk) 13:18, 18 November 2014 (UTC)
replies: text: Actually no, you are overdoing it. However with respect to medical fact, we cannot be too cautious. User:Fred Bauder Talk 14:58, 18 November 2014 (UTC)
thread_title: AHA guidelines

message: I made a series of edits, each with its own edit note, to bring the article into line with MEDMOS and MEDRS.  The article previously had a section on "Clinical trial controversy" as you can see in this old version. i had previously posted a question about what to do with the controversy section at WikiProject Medicine here.   Thought about what people wrote there, and what the content of the "controversies" section actually was, and edited accordingly.  Seems to me that the FDA approved the drug knowing full well that there was no mortality or CV morbidity data, and doctors knew that too, from day one.  It is unclear to me what the "controversy" is or was; ambiguity is not controversy.  There was definitely ambiguity in that nobody has known if the drug is actually driving good clinical outcomes or not.  The article still communicates that. Jytdog (talk) 13:42, 18 November 2014 (UTC)
thread_title:  clean up, clinical trials controversies section 

message: Have moved this 
"The IMPROVE-IT trial was a major trial intended to address the important question of whether further reductions in low-density lipoprotein cholesterol (LDL-C) achieved by adding ezetimibe to a statin drug would improve cardiovasacular outcomes. The study involved 18,444 patients who were at high risk of future cardiovascular events and had already stably recovered from an acute coronary syndrome event. While the results have not been published under peer review and have thus undergone only limited scientific scrutiny, the IMPROVE-IT investigators reported the final results of IMPROVE-IT at the American Heart Association Scientific Sessions 2014. The investigators report that adding ezetimibe to the statin drug simvastatin reduced LDL-C by an additional 15-mg/dL, relative risk of cardiovascular events by 6.4%, and relative risk of cardiovascular death, myocardial infarction (heart attack), or stroke by 10% relative to simvastatin alone; specifically, 34.7% of patients given simvastatin alone suffered a cardiovascular event, while only 32.7% of patients receiving ezetimibe/simvastatin combination therapy did."
Issues include
#It reads like a press release
#The study has not been published yet
Thus IMO we should wait. Doc James (talk · contribs · email) 00:19, 24 December 2014 (UTC)
replies: text: As discussed above, yes we wait - not just until the study is published but even further, until there is a review that discusses the study results. Jytdog (talk) 02:11, 24 December 2014 (UTC)
replies: text: Yes I do not image it will take too long unless there are issues. Doc James (talk · contribs · email) 02:50, 24 December 2014 (UTC)
thread_title: Addition

message: Wondering why there's no history for ezetimibe (like who/which company developed it).  — Preceding unsigned comment added by 155.91.28.142 (talk) 20:34, 21 January 2021 (UTC)
thread_title:  History of ezetimibe